Skip to main content
. 2023 May 19;129(2):291–300. doi: 10.1038/s41416-023-02298-8

Table 1.

Patient characteristics.

Number of patients Part A (N = 14) Part B (N = 22)
Age, years, mean (range) 62 (44-79) 56 (32-74)
Sex, male 9 (64%) 15 (68%)
Ethnicity
 White 9 (64%) 19 (86%)
 Black/Asian/other 5 (36%) 3 (14%)
ECOG PS
 0 4 (29%) 10 (45%)
 1 10 (71%) 12 (55%)
Current or former smoker 3 (21%) 11 (50%)
Locally advanced disease at initial presentation 6 (43%) 2 (9%)
Site of origin
 Pancreas/Biliary 2 (14%) 5 (23%)
 Other gastrointestinal 2 (14%) 11 (50%)
 Genitourinary 4 (29%) 1 (5%)
 Gynaecologic 1 (7%) 1 (5%)
 Head/neck 3 (21%) 0
 Unknown 2 (14%) 4 (18%)
Histology
 Large cell 2 (14%) 6 (27%)
 Small cell 10 (71%) 8 (36%)
 Mixed tumours 1 (7%) 3 (14%)
 Not otherwise specified 1 (7%) 5 (23%)
Median Ki-67 75%* (range 31–91%) 75% (range 30–95%)**
Number of prior lines of systemic therapy, median (range) 2 (1–8) 1 (1–4)
Prior platinum-based therapy (%) 14 (100%) 22 (100%)

*Available from the tumours of N = 10 patients (71%).

**Available from the tumours of N = 18 patients (82%).